Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Lixivaptan

Generic Name: Lixivaptan

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₁ClFN_₃O_₂

CAS Number: 168079-32-1

Unique Ingredient Identifier: 8F5X4B082E

Overview

No overview information available.

Background

No background information available.

Indication

Investigated for use/treatment in hyponatremia and congestive heart failure.

Associated Conditions

No associated conditions information available.

Clinical Trials

Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303

Phase 3

Terminated

Posted: 2022/01/26

Sponsor:

Palladio Biosciences

ID:NCT05208866

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease

Phase 3

Terminated

Posted: 2019/11/05

Sponsor:

Palladio Biosciences

ID:NCT04152837

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease

Phase 3

Terminated

Posted: 2019/08/21

Sponsor:

Palladio Biosciences

ID:NCT04064346

Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease

Posted: 2018/10/24

Sponsor:

Palladio Biosciences

ID:NCT03717181

The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Phase 2

Completed

Posted: 2018/04/04

Sponsor:

Palladio Biosciences

ID:NCT03487913

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy